Ms. Ball has served as our Senior Vice President, Corporate Strategy and Chief Financial Officer since 2017. Ms. Ball has approximately 25 years of experience in the life-sciences industry.
Prior to joining Menlo Therapeutics, Ms. Ball served as Senior Vice President and Chief Financial Officer of Relypsa, Inc., a publicly-listed pharmaceutical company, from 2012 to 2016. At Relypsa, Ms. Ball was responsible for finance, investor relations, corporate development, and various other administrative functions. Ms. Ball led Relypsa’s IPO in November 2013 and in 4 years raised over $675 million in various equity and debt financings to fund the company’s growth. Additionally, Ms. Ball was actively involved with executing partnerships with Sanofi and Vifor Fresenius Medical Care Renal Pharma, and the company’s acquisition by Galenica for over $1.5 billion.
From 2005 to 2011, Ms. Ball was Senior Vice President of Finance and Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc. (acquired by Amgen), a drug discovery company. At KAI, she was responsible for finance, administration and strategic planning. She was involved in venture capital financings, pharmaceutical partnerships and KAI’s acquisition by Amgen.
Earlier in her career, Ms. Ball served as Vice President of Finance at Exelixis, Inc., a biotechnology company, from 2000 to 2005, where she was involved in four acquisitions, Exelixis’ initial public offering and other financings. Before joining Exelixis, Ms. Ball was a senior manager in Ernst & Young’s life sciences audit practice.
Ms. Ball holds a B.S. from Babson College. She serves on the Board of Directors of Forty Seven, Inc. and the National Kidney Foundation Northern California Chapter.